0001225208-21-004323.txt : 20210302
0001225208-21-004323.hdr.sgml : 20210302
20210302175952
ACCESSION NUMBER: 0001225208-21-004323
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210227
FILED AS OF DATE: 20210302
DATE AS OF CHANGE: 20210302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: YOUNG JOHN D
CENTRAL INDEX KEY: 0001551792
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-03619
FILM NUMBER: 21705688
MAIL ADDRESS:
STREET 1: C/O CORPORATE SECRETARY
STREET 2: 235 EAST 42ND ST.
CITY: NEW YORK
STATE: NY
ZIP: 10017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PFIZER INC
CENTRAL INDEX KEY: 0000078003
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 135315170
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 235 E 42ND ST
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 2125732323
MAIL ADDRESS:
STREET 1: 235 E 42ND ST
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER COMPANY:
FORMER CONFORMED NAME: PFIZER CHARLES & CO INC
DATE OF NAME CHANGE: 19710908
4
1
doc4.xml
X0306
4
2021-02-27
0000078003
PFIZER INC
PFE
0001551792
YOUNG JOHN D
PFIZER INC.-CORP. SECRETARY
235 EAST 42ND ST.
NEW YORK
NY
10017
1
Group President
Common Stock
2021-02-27
4
M
0
129419.0000
22.3500
A
575282.0000
D
Common Stock
2021-02-27
4
F
0
23194.0000
33.4900
D
552088.0000
D
Common Stock
2021-02-27
4
F
0
82057.0000
34.6400
D
470031.0000
D
Common Stock
2446.0000
I
By Rule 16b-3 Plan
Common Stock
1589.0000
I
By Trustee under the Pfizer Share Ownership Plan
Stock Appreciation Rights
22.3500
2021-02-27
4
M
0
129419.0000
0.0000
D
2021-02-27
2021-02-27
Common Stock
129419.0000
0.0000
D
The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
Price is the closing price of Pfizer common stock on February 26, 2021.
The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
In connection with the completed spinoff and combination of the Upjohn business with Mylan to create Viatris, and in accordance with their terms, adjustments were made to stock units, by providing additional Pfizer total shareholder return units (Stock Appreciation Rights) to plan participants in lieu of the Viatris dividend provided to shareholders, in order to maintain the same value post-transaction as the value of the outstanding awards prior to the transaction (subject to rounding).
Susan E. Grant, by power of atty., for John D. Young
2021-03-02